Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples